Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Penumbra Inc. (PEN)

NYSE: PEN · Surgical & Medical Instruments & Apparatus · Alameda, CA

Our rating: Neutral

Neutral reaffirmed at $318.95, moderate conviction, October 30, 2026.

Breaks if: The Neutral call turns Positive if Penumbra reports revenue growth above 20% alongside net margin expansion above 15% for two consecutive quarters — evidence the company is growing into rather than merely sustaining its multiple. It turns Cautious if revenue growth decelerates below 10% in any single reported quarter, or net margin falls below 10% for two consecutive quarters, signaling that the embedded growth assumption is breaking rather than being met.

Key figures

Market value$12.6B
Revenue, last 12 months$1.6B
Net income, last 12 months$157M
Free cash flow, last 12 months$200M
Price to earnings80.1×
Free cash flow yield1.6%
Dividend yield0.0%
Operating margin12.1%
Return on equity10.7%
Beta to the S&P 5000.46
Volatility, annualized33.3%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$410M15.6%$1.07$26M
June 30, 2026$390M14.9%$0.88$33M
March 31, 2026$375M15.6%$0.82$73M
December 31, 2025$385M22.1%$1.20$68M
September 30, 2025$355M17.8%$1.17$42M
June 30, 2025$339M13.4%$1.15$29M
March 31, 2025$324M16.3%$1.00$36M
December 31, 2024$316M10.8%$0.87$46M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

8 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.